EagleClaw Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

EagleClaw Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.74M	Buy	7,535 +150	+2%	+$66.5K	0.5%	57
2026 Q1	$3.3M	Hold	7,385	–	–	0.46%	54
2025 Q4	$3.35M	Hold	7,385	–	–	0.48%	55
2025 Q3	$2.89M	Sell	7,385 -200	-3%	-$83.6K	0.4%	62
2025 Q2	$3.38M	Sell	7,585 -10	-0.1%	-$4.61K	0.5%	52
2025 Q1	$3.68M	Sell	7,595 -35	-0.5%	-$16.3K	0.58%	49
2024 Q4	$3.07M	Buy	7,630 +5	+0.1%	+$2.32K	0.49%	59
2024 Q3	$3.55M	Buy	7,625 +200	+3%	+$96.1K	0.59%	51
2024 Q2	$3.48M	Sell	7,425 -100	-1%	-$43.4K	0.63%	47
2024 Q1	$3.15M	Hold	7,525	–	–	0.57%	54
2023 Q4	$3.06M	Sell	7,525 -35	-0.5%	-$12.9K	0.64%	51
2023 Q3	$2.63M	Buy	7,560 +120	+2%	+$42K	0.6%	53
2023 Q2	$2.62M	Hold	7,440	–	–	0.6%	56
2023 Q1	$2.34M	Hold	7,440	–	–	0.55%	58
2022 Q4	$2.15M	Hold	7,440	–	–	0.52%	64
2022 Q3	$2.15M	Hold	7,440	–	–	0.6%	58
2022 Q2	$2.1M	Hold	7,440	–	–	0.57%	60
2022 Q1	$1.94M	Hold	7,440	–	–	0.45%	64
2021 Q4	$1.63M	Buy	+7,440	New	+$1.45M	0.36%	65

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

EagleClaw Capital Management's VRTX Position: Q2 2026 in Review

EagleClaw Capital Management increased its Vertex Pharmaceuticals (VRTX) stake by 2% in Q2 2026, buying an estimated $66.5K and bringing the position to 7,535 shares worth $3.74M. The position accounts for 0.5% of the portfolio, ranked #57.

EagleClaw Capital Management first reported a position in VRTX in Q4 2021 and has held it in 19 quarters since. 1,761 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

EagleClaw Capital Management held 7,535 shares of Vertex Pharmaceuticals worth $3.74M as of Q2 2026.
EagleClaw Capital Management bought 150 Vertex Pharmaceuticals shares in Q2 2026, an estimated $66.5K.
Vertex Pharmaceuticals made up 0.5% of EagleClaw Capital Management's portfolio in Q2 2026, its #57 holding.
EagleClaw Capital Management first reported a position in Vertex Pharmaceuticals in Q4 2021 and has held it in 19 quarters since.
1,761 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on EagleClaw Capital Management's 13F filing for Q2 2026, filed 10 Aug 2026.